RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.